Breaking News

Juncell Therapeutics Opens New TIL Manufacturing Facility

With a total area exceeding 16,000 square meters, the new facility houses the company's production, quality, data, and operation centers.

Shanghai Juncell Therapeutics Co. Ltd., a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, has opened its new TIL manufacturing facility located at Anting International Medical Industry Park in Jiading District, Shanghai, China.
 
Juncell Therapeutics’ latest facility, with a total area exceeding 16,000 square meters, houses the company’s production, quality, data, and operation centers. This facility, with a designed production capacity of TIL products for 6,000-10,000 patients annually, represents a significant milestone. The establishment of the facility will significantly promote the development of high-quality TIL products and the transformation of disruptive technologies into new quality productive forces.
 
Officials from National Development and Reform Commission, Shanghai Municipality, Jiading District, Anting Town, and Anting International Medical Industry Park, as well as representatives from various investment institutions, clinical experts, and executives from leading industrial companies, attended the ceremony to witness the grand opening of Juncell’s high-standard TIL manufacturing facility.
 
Dr. Jin Huajun, the founder of Juncell Therapeutics, expressed his heartfelt gratitude to all the leaders and guests present at the ceremony.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters